CPTR Newsletter – April 2018 CPTR Newsletter – April 2018 In this issue: ReSeqTB to be Adopted for WHO Surveillance of Drug-Resistant TB New Collabora
Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path
Tucson-based Critical Path Institute emerging as top drug-research organization President and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published Februa
Critical Path to TB Drug Regimens (CPTR) 2018 Annual Workshop, postponed Critical Path Institute and Bill & Melinda Gates Foundation have decided to postpone the Critical Path to TB Drug Regimens Wor
Critical Path Innovation Meeting On September 14, 2017, Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium and Electronic Patient-Repor
miR-122 An Exploratory Biomarker of Liver Injury: An Industry Perspective on the State of the Science and Experiences Pre-Clinically and Clinically The Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) hosted a webinar focused on providing an industry pers
New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
PTC Meets Its Deliverables April 11, 2017 Dear Colleagues, In the fall of 2015 C-Path established the Pediatric Trials Consortium (PTC), with the go